The pharmacoepidemiology of antipsychotic medications for canadian children and adolescents: 2005-2009

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 6, 2011, Pages 537-543

  Pringsheim, Tamara ^a   Lam, Darren ^a   Patten, Scott B ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; DEXAMPHETAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; ZIPRASIDONE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CANADA; CHILD; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PHARMACOEPIDEMIOLOGY; PRESCHOOL CHILD; PRESCRIPTION; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CANADA; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG UTILIZATION; HUMANS; INFANT; MENTAL DISORDERS; PHARMACOEPIDEMIOLOGY; SEROTONIN UPTAKE INHIBITORS;

EID: 84555189937     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2010.0145     Document Type: Article

References (26)

1. Aman M, De Smedt G, Derivan A, Lyons B, Findling R, Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002. (Pubitemid 34832715)
2. Armenteros J, Lewis J, Davalos M: Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 26:558-565, 2007. (Pubitemid 46642572)
3. Carleton B, Foerster V, Warren L, Smith MA: Post marketing phar-macosurveillance in Canada. A background paper prepared for the Working Conference on Strengthening the Evaluation of Real World Drug Safety and Effectiveness, Ottowa, Ontario, August 31, 2005.
4. Catlin G, Will P: The National Population Health Survey: Highlights and initial developments. Health Rep 4:313-319, 1992.
5. Correll C, Manu P, Olshanskiy V, Napolitano B, Kane J, Malhotra A: Cardiometabolic risk of second generation antipsychotic medications during first time use in children and adolescents. JAMA 302:1765-1773, 2009.
6. DelBello M, Schwiers M, Rosenberg L, Strakowski S: A double-blind, randomized, placebo-controlled study of quetiapine as ad-junctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 41:1216-1223, 2002. (Pubitemid 38338041)
7. Doey T, Handelman K, Seabrook J, Steele M: Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry 52:363-368, 2007. (Pubitemid 46997310)
8. Findling R, Robb A, Nyilas M, Forbes R, Jin N, Ivanova S, Marcus R, McQuade R, Iwamoto T, Carson W: A multiple-center, randomized double-blind placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1369-1372, 2008.
9. Haas M, Unis A, Armenteros J, Copenhaver M, Quiroz J, Kushner S: A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 19:611-621, 2009.
10. Hammad TA, Laughren T, Racoosin J: Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339, 2006. (Pubitemid 43345358)
11. Kryzhanovskaya, Schulz S, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M: Olanzapine versus placebo in adolescents with schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:60-70, 2009.
12. Kumra S, Frazier J, Jacobsen L, McKenna K, Gordon C, Lenane M, Hamburder S, Smith A, Albus K, Alaghband-Rad J, Rapoport J: Childhood-onset schizophrenia: A double-blind clozapine-halo-peridol comparison. Arch Gen Psychiatry 53:1090-1097, 1996. (Pubitemid 26422059)
13. Luby J, Mrakotsky C, Stalets M, Belden A, Heffelfinger A, Williams M, Spitznagel E: Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc Psychopharmacol 16:575-587, 2006. (Pubitemid 44737212)
14. Marcus R, Owen R, Kamen L, Manos G, McQuade R, Carson W, Aman M: A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110-1119, 2009.
15. Nagaraj R, Singhi P, Malhi P: Risperidone in children with autism: Randomized, placebo-controlled, double-blind study. J Child Neurol 21:450-455, 2006. (Pubitemid 44069792)
16. Olfson M, Blanco C, Liu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685, 2006. (Pubitemid 43848299)
17. Patel N, Sanchez R, Johnsrud M, Crismon M: Trends in antipsychotic use in Texas Medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 12:221-229, 2002. (Pubitemid 35191348)
18. Pliszka S,Crismon L, Hughes C, Conners C, Emslie G, et al: The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of ADHD. J Am Acad Child Adolesc Psychiatry 45:642-657, 2006. (Pubitemid 43833097)
19. Rani F, Murray ML, Byrne PJ, Wong IC: Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121:1002-1009, 2008.
20. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M: A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163:402-410, 2006. (Pubitemid 44469381)
21. Sallee F, Kurlan R, Goetz C, Signer H, Scahill L, Law G, Dittman V, Chappell P: Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299, 2000. (Pubitemid 30127607)
22. Sethi K, Morgan J. Drug-induced movement disorders. In: Parkinson's Disease and Movement Disorders. Edited by J. Jankovic, E. Tolosa. Philadelphia: Lippincott Williams and Wilkins; 2007; pp. 394-408.
23. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, The Risperidone Conduct Study Group: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002. (Pubitemid 38338050)
24. Statistics Canada. National Longitudinal Survey of Children and Youth (NLSCY). Detailed information for 2006-2007 (Cycle 7); 2009.
25. Available at www.statcan.gc.ca/cgibin/imdb/p2SV.pl?Function= getSurvey&SDDS=4450&lang=en&db=imdb&adm=8&dis=2 (last accessed October 23, 2009).
26. Valluri S, Zito J, Safer D, Zuckerman I, Mullins C, Korelitz J: Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new onset depression. Med Care 28:947-954, 2010.